Lymphoma and leukemia cell therapy by humanized antibodies

• Unité de recherche: INNOSUISSE
• Numéro de projet: 46049.1 IP-LS
• Titre du projet anglais: Lymphoma and leukemia cell therapy by humanized antibodies

Description succincte (Allemand)

Lymphoma and leukemia cell therapy by humanized antibodies

Description succincte (Anglais)

Lymphoma and leukemia cell therapy by humanized antibodies

Résumé des résultats (Abstract) (Allemand)

Abologix developed humanized monoclonal antibodies (mAbs) directed against the adhesion molecule C (JAM-C), a novel cancer target expressed on multiple B-cell lymphomas and leukemia cells. Classical treatment often fails due to resistance, but JAM-C still can be targeted and used for rescue.